Status:
RECRUITING
A Study to Evaluate the Efficacy and Safety of AD-218
Lead Sponsor:
Addpharma Inc.
Conditions:
Mixed Dyslipidemia
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-218
Detailed Description
Condition or disease : Mixed Dyslipidemia Treatment Drug : AD-218, AD-218A, Placebo of AD-218, Placebo of AD-218A
Eligibility Criteria
Inclusion
- A man or woman over 19 years old.
- Sign on ICF prior to study participation
Exclusion
- History of Fibromyalgia, Myopathy etc (CK ≥ 2 X ULN)
- Other exclusions applied
Key Trial Info
Start Date :
July 27 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
520 Patients enrolled
Trial Details
Trial ID
NCT05400317
Start Date
July 27 2022
End Date
June 30 2026
Last Update
February 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yeongnam University Hospital
Daegu, Nam-gu, South Korea, 42415